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Abstract
Background: Adhesive capsulitis (AC) of the shoulder, also known as frozen shoulder, causes substantial pain and
disability. In cases of secondary AC, the inflammation and fibrosis of the synovial joint can be triggered by trauma or
surgery to the joint followed by extended immobility. However, for primary AC the inciting trigger is unknown. The
burden of the disorder among the elderly is also unknown leading to this age group being left out of therapeutic
research studies, potentially receiving delayed diagnoses, and unknown financial costs to the Medicare system. The
purpose of this analysis was to describe the epidemiology of AC in individuals over the age of 65, an age group little
studied for this disorder. The second purpose was to investigate whether specific medications, co-morbidities, infections, and traumas are risk factors or triggers for primary AC in this population.
Methods: We used Medicare claims data from 2010–2012 to investigate the prevalence of AC and assess comorbid
risk factors and seasonality. Selected medications, distal trauma, and classes of infections as potential inflammatory
triggers for primary AC were investigated using a case–control study design with patients with rotator cuff tears as
the comparison group. Medications were identified from National Drug codes and translated to World Health Organization ATC codes for analysis. Health conditions were identified using ICD9-CM codes.
Results: We found a one-year prevalence rate of AC of approximately 0.35% among adults aged 65 years and older
which translates to approximately 142,000 older adults in the United States having frozen shoulder syndrome. Diabetes and Parkinson’s disease were significantly associated with the diagnosis of AC in the elderly. Cases were somewhat
more common from August through December, although a clear seasonal trend was not observed. Medications,
traumas, and infections were similar for cases and controls.
Conclusions: This investigation identified the burden of AC in the US elderly population and applied case–control
methodology to identify triggers for its onset in this population. Efforts to reduce chronic health conditions such as
diabetes may reduce seemingly unrelated conditions such as AC. The inciting trigger for this idiopathic condition
remains elusive.
Keywords: Adhesive capsulitis, Frozen shoulder, Stiff shoulder, Risk factors, Epidemiology
Background
Adhesive capsulitis (AC), also known as frozen shoulder, is a common and debilitating shoulder condition,
yet its cause remains largely unknown. The prevalence is
*Correspondence: smsaras@clemson.edu
1
School of Nursing, Clemson University, 436 Edwards Hall, Clemson, SC,
USA
Full list of author information is available at the end of the article

typically reported to be 2–5% [1, 2], although estimates
range as low as 0.5% [3] or as high as 10% [4]. The condition is most common among adults aged 40 to 70 years,
but reported ages range from 27 to 85 [5]. Symptoms
of this condition are shoulder joint pain with motion or
pain during sleep followed by stiffness and dramatically
reduced range of motion. The disability in the shoulder
can last over a period of one or more years during which
range of motion is slowly restored. For some patients, full
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range of motion is not restored even after four years [5,
6]. The typical time course for AC follows three stages [2]:
a painful “freezing” stage where pain precedes reduced
range of motion lasting 10–36 weeks. The next stage,
lasting 4–12 months, is the “frozen” stiff stage where pain
is reduced but range of motion remains impaired. The
final stage, lasting 5–26 months, is the “thawing” stage
where range of motion is gradually improves.
The pathophysiology of AC supports the theory that the
condition results from a complex chain of events starting with inflammation leading to fibrosis and contracture
of the shoulder capsule, the so-called “inflammatoryfibrotic cascade” [7]. During this cascade, inflammation,
with cytokine proliferation lead to increased fibroblast
proliferation, increased vascularization and new nerve
growth, which may explain the pain reported by patients
[7–12]. These factors in turn lead to increased and dysregulated collagen fiber deposition. Collagen fibers
adhere to the glenohumeral ligaments, tendons, and joint
surfaces causing contracture and joint stiffening. Thus,
even after the inflammation is reduced, the adhesions
remain greatly restricting motion [8, 9, 12]. It remains to
be discovered what the inciting factor is that triggers this
cascade and leads to the acute onset of AC.
AC is typically referred to as “primary” or “secondary”. Primary AC is idiopathic AC where examination
and history cannot explain the development of the condition [2] whereas secondary AC develops due to preexisting shoulder disorders or shoulder trauma [13] or
post-mastectomy from breast cancer [14]. Primary AC is
idiopathic with the cause unknown. Several risk factors
for primary AC have been identified including diabetes
[5, 15–17], thyroid disorders [15, 16, 18, 19], rheumatoid
arthritis [13], gout [20], hyperlipidemia [17, 21] and Parkinson’s disease [22].
Rationale

Despite what is known about the pathophysiology of
AC and the associated risk factors, the trigger that sets
primary frozen shoulder syndrome in motion is largely
unknown and few studies have been undertaken to
investigate triggers. There have been several small studies that suggest that the trigger for AC may be the usage
of systemic medications, distal trauma, or perhaps there
is a seasonal component that directly or indirectly initiates the disorder. Much of the sparse literature related to
potentially medication-associated AC is based upon case
reports or small case series that merit follow-up in larger
samples [23–31]. Trauma has been suggested to generate
systemic inflammation affecting areas distant from the
site of trauma [32]. Another line of evidence supporting
a possible role for infection as a trigger is the suggestion
of seasonal occurrence of AC. The classic investigation
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by Nevasier (1945) reported 7 out of 8 patients had an
onset during the winter months [33], suggesting a seasonal exposure akin to seasonality observed for influenza.
Spouses are reported to have AC co-occur somewhat
more than siblings [5] suggesting a shared environmental exposure as a possible risk factor. This observation by
Hand et al. (2008) has received little notice or follow-up.
Most recently, Ascani et al. (2021) report an increase in
AC after COVID-19, supporting a potential association
between viral infection and AC [34].
AC has generally been described as a condition affecting late middle-aged adults, and little has been written
about the condition in the elderly population. Diabetes
is the best studied risk factor for AC and the prevalence
of diabetes is much higher in the ≥ 65 year age group
(26.8%) than in the 18–44 years (4.2%) or 45–64 year age
group (17.5%) making this group potentially more at risk
[35]. With a large and growing population of older adults
in the US, investigating the prevalence and triggers for
this condition are warranted. Therefore, in this investigation, the prevalence of AC in the US Medicare population
was determined. Then, using the cases we identified as
primary AC and a control group without AC, we explore
the hypothesis that AC may be triggered by an infection,
trauma, or medications.

Methods
Data and sample

This study used complete Medicare Part B (fee-for-service) administrative claims data from the years 2010–
2012 for all Medicare beneficiaries diagnosed with AC
in 2011 (N = 92,437). The use of complete Medicare
administrative data enabled patient healthcare utilization to be tracked across inpatient and outpatient settings
and covered patients from all states in the United States.
Participants in Medicare Part C, also known as Medicare Advantage, is a separately administered program
and the data were not available for analysis. This project
was reviewed by the University of South Carolina Institutional Review Board and determined to be not human
research.
AC prevalence cohort

Prevalence of AC (primary or secondary) in the Medicare population was determined by identifying Medicare
beneficiaries with at least one diagnosis of AC in 2011 as
defined by having an International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM)
codes: 726.00, using Medicare Part B carrier claims. To
calculate the denominator for prevalence estimates, the
Centers for Medicare and Medicaid Services published
data were used to determine the total population of
Medicare beneficiaries over age 65 (40,685,908 people)
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and the subset of those with fee-for-service Part B coverage (26,756,183 people) [36]. Approximately two-thirds
of Medicare beneficiaries over age 65 are covered by
Medicare Part B.
Primary AC cohort

As this study focuses on identifying triggers for new, primary AC diagnoses, a subset of the AC prevalence cohort
representing those Medicare beneficiaries with primary
AC was identified. In order to best identify those beneficiaries with primary AC, a series of clinically guided
inclusion criteria were applied. First, all Medicare beneficiaries with an index (first) shoulder visit in 2011 and no
previous shoulder diagnoses in the 365-days prior were
identified. This included 192 ICD-9-CM shoulder related
diagnosis codes, including AC and RCT. The index shoulder date was defined for each beneficiary as the first date
where a shoulder diagnosis was received in 2011. Of that
group, individual beneficiaries with a diagnosis of AC
(ICD-9-CM codes: 726.00) within 90 days of the index
shoulder visit and an x-ray or MRI within 30 days of the
index shoulder visit were included. Given that diagnostic
imaging is routinely used in the AC diagnosing process to
rule out other clinically similar shoulder diagnoses, this
inclusion requirement increased the confidence in the
diagnosis of AC and the likelihood the case was receiving
an initial diagnosis of AC. Following the diagnostic imaging service, beneficiaries also had to have a subsequent
AC diagnosis claim within 180 days of their first AC diagnosis claim. The selection of the 30, 90, and 180 day windows was based upon expertise of the investigators and
the typical pattern of care when making a new diagnosis.
Given the known direct association between mastectomy and AC diagnosis [14], any beneficiaries that
had a mastectomy (CPT 85.2, 85.3, 85.4) were excluded
from the analysis. Patients with fracture, dislocations,
and sprains involving the shoulder were also excluded as
these are known causes of secondary AC [13]. Furthermore, because rotator cuff (RC) tears were used as our
control group, any AC beneficiaries who had a concurrent RC diagnosis were also excluded from the study. The
presence of co-morbid chronic health conditions such
as diabetes were not exclusion criteria as these factors
are considered risk factors and not acute triggers. Additional inclusion criteria applied to assure complete data
included (1) continuous enrollment in fee-for-service
Medicare Part A and Part B from 365-days prior to 365days after the index shoulder diagnosis and no enrollment
in Medicare Part C (also known as Medicare Advantage
plans) during the study period, (2) aged 66 years on the
index shoulder visit, and (3) residence within the continental United States or Hawaii. The final residency criteria excludes Medicare beneficiaries who may obtain
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medical care outside the U.S. Medicare system and thus
would have incomplete data. The minimum age criterion
of 66 years was used to ensure enrollment in the Medicare system for a year prior to the index shoulder diagnosis. Complete patient inclusion criteria can be found in
Fig. 1. The final primary AC case cohort included 7,232
Medicare beneficiaries.
Rotator cuff controls selection

A group of beneficiaries with a rotator cuff tear diagnosis in 2011 were selected as controls in our study. Rotator cuff tear was selected because of its similar clinical
presentation but distinct etiology, and because it has
been used as a control group in two studies of AC [37,
38]. Similar inclusion criteria were applied to identify the
control group using Medicare Part B claims. Individual
patients with a diagnosis of rotator cuff tear (ICD-9-CM
codes: 727.61, 840.3, 840.4 covering partial thickness
tears, bursal-sided tears, full thickness tears, massive
tears) within 90 days of the index shoulder visit and an
x-ray or MRI within 30 days of the index shoulder visit
were included. Medicare beneficiaries also had to have
a subsequent rotator cuff tear diagnosis claim within
180 days of their first rotator cuff diagnosis claim within
2011. Patients with any shoulder diagnosis in the 365days prior to their index shoulder diagnosis in 2011 were
excluded from the study. Additionally, any beneficiaries that had a concurrent diagnosis of AC were excluded
from the control cohort. Additional inclusion criteria
applied to assure complete data included continuous
enrollment, aged 66 years on the index shoulder data,
and residence within the continental United States. The
final rotator cuff tear control cohort included 70,890 eligible Medicare beneficiaries.
Case–control matching process

Controls were matched to cases in a 3:1 ratio based on
beneficiary age within 4 years (± 2 years) and gender.
One older case was only matched to one control due to
limitations in control sample at the age range. The final
matched RC control group was 21,694 beneficiaries.
Cases and controls were selected according to the flow
chart described in Fig. 1.
Medication and vaccine measures

Medication use in the 180 days prior to index shoulder
diagnosis was obtained from Medicare National Drug
Code (NDC) data and translated to the World Health
Organization (WHO) Anatomical Therapeutic Chemical
(ATC4) classification code [39] using the cross-reference
coding developed by Kury et al. [40]. An exposure period
of 180-days prior to index shoulder diagnosis was chosen
to allow time for initiation of the inflammatory pathway
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Fig. 1 Flow chart of the selection of cases and controls. FFS- Fee-for-service beneficiaries. Does not include Medicare Advantage plan participants

as well as account for delays between onset of AC and
accessing medical care. Prior case reports indicated
wide variation in time between initiation of medication
and onset of AC, such as 10 days for fluoroquinolones
[26] and 3 to 5 months for primidone, metalloproteinase

inhibitors, and acitretin [25, 27, 30]. Six drug classes previously noted in the literature to increase the risk of AC
were studied: fluoroquinolones [25], barbiturates [24],
antituberculosis agents [31], protease inhibitors [28, 29],
retinoids [27], and metalloproteinase inhibitors [30]. An
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additional class of antiviral agents was examined to serve
as a potential proxy measure for exposure to a viral agent.
The hierarchical nature of the ATC4 code allowed
classification into categories of medication and specific
usages. The following ATC4 codes were used: J01M to
capture quinolones, J04A for antimycobacterials to treat
tuberculosis including isoniazid, N03AA for any barbiturate, D05BB and D10BA for retinoids for systemic
use, B02AB for proteinase inhibitors, J05AE for protease
inhibitors, and J05A for antivirals. Medication utilization
was identified using Part D claims. Receipt of an influenza or pneumococcal vaccine in the 180 days prior to
index diagnosis was determined from Healthcare Common Procedure Coding System (HCPCS) codes in Part
B claims: 90,630, 90,653, 90,654, 90,655, 90,656, 90,657,
90,658, 90,660, 90,661, 90,662, 90,672, 90,673, 90,674,
90,682, 90,685, 90,686, 90,687, 90,688, 90,689, 90,756,
Q2035, Q2036, Q2037, and Q2038.
Infectious diseases and trauma exposure

Diagnosis codes were examined for infectious disease and
trauma diagnoses occurring 180-days prior to the index
shoulder diagnosis. Categories of infectious diseases were
created following prior classification systems [13, 41, 42].
The five most common infectious disease groups, occurring in at least 3% of the study population were examined in the analysis. The minimum of 3% was selected
for pragmatic reasons to identify a common trigger. With
an estimate of 3% exposure in cases, the study had 99.6%
power to detect an odds ratio of 1.5 or higher. The infectious disease groups included mycoses (ICD-9-CM codes
110.0–118.0), upper respiratory tract infections (ICD9-CM codes 460.X-466.X, 475.X), lower respiratory tract
infections (ICD-9-CM codes 480.X-489.X, 490.X, 510.X,
513.X), infections of the kidney and urinary tract (ICD9-CM codes 590.0–590.9, 599.0, 595–595.9, 597.X), and
skin infections (ICD-9-CM codes 680.X-686.X, 695.5).
Trauma categories excluded trauma to the shoulder
and were divided into fracture, dislocation, or sprains
(ICD-9-CM codes 800.X-848.X) and other traumatic
injuries (ICD-9-CM codes 850.X-854.X, 870.X-879.X,
880.X-887.X, 890.X-897.X, 900.X-904.X, 920.X-924.X,
925.X-929.X, 950.X-957.X, and 959.X) based upon classification used by Peterson et al. [32].
Patient characteristics and comorbid conditions

Patient demographic characteristics were measured by
cross referencing the 2011 Beneficiary Summary files
from Medicare. Specific patient-level variables included
age, sex, race, and dual-eligibility for Medicare and Medicaid status on the index shoulder diagnosis date. General
patient health was measured using Part A and B Medicare spending in the year prior to the index shoulder date,
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the Charlson Comorbidity Index (CCI), and the Frailty
Risk Index (FRI). CCI is a validated measure of burden of
disease [43–45]. Comorbidities are weighted from 1 to 6
for mortality risk and disease severity and then summed
to form the total CCI score [43–45]. The FRI score is a
validated instrument for assessing frailty among older
persons [46]. Comorbid conditions that have been previous associated with AC were identified using ICD-9-CM
codes as follows: thyroid disorder (240–246), Type 1 and
Type 2 diabetes (250.XX-250.93), hyperlipidemia (272.0–
272.9), hypertension (401–405), rheumatoid arthritis
(714.0), and gout (274).
Statistical analysis

Descriptive statistics were calculated for determining the
overall prevalence of AC and the demographics of the AC
cohort. Then descriptive statistics, followed by t-tests or
Chi-square tests, were used to assess the association of
AC presence and the risk factors (infections, traumas,
medications, and patient demographics) individually.
A P-value < 0.05 was considered statistically significant.
Seasonality of AC presence was assessed by estimating the proportions of new primary AC cases diagnosed
per month with 95% confidence intervals, and using the
intervals to identify months that were higher or lower
than typical. Logistic regression models were used next
to assess the association with AC and the risk factors in
a combined model. Logistic regression results were presented as 95% confidence intervals for the odds ratios. A
95% confidence interval for odds ratios that excluded 1.0
was considered to be evidence of a statistically significant
association. Because the case–control matching was performed on only age and gender (and thus considered to
be a loose match), unconditional logistic regression was
performed [47]. A conditional model was also run to verify similar results.

Results
Prevalence of AC in the US Medicare population

We found 92,437 individuals over age 65 with a diagnosis of AC in the Part-B beneficiary population, representing 4% of those with a shoulder claim. We estimate
that the one-year prevalence for AC in the over 65-year
age group to be 0.35% (92,437/26,756,183 Part-B beneficiaries). This prevalence of 0.35% translates to an estimated total 142,000 people over age 65 with AC across
the U.S. (0.35% of the 40,685,908 total Medicare for the
aged population). Average one-year Medicare spending, in the year prior to diagnosis, for those beneficiaries
with a diagnosis of AC in 2011 was substantially higher
($14,176) than the average spending per Medicare beneficiary in 2011 ($10,756) [48].
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Two thirds of AC patients were female, and the mean
age of the AC cohort was 75.7 years (Table 1). White
(86.3%), Black (6.7%), and Asian (2.8%) were the most
common reported racial categories for patients with
AC. Patients came from all regions of the United States,
and two-thirds were younger than age 76 years. Using
the Charlson Comorbidity Index as a measure of general health status, approximately 51.1% of individuals
with AC had a CCI score of 2 or higher, indicating more
co-morbidities [43, 45]. Common co-morbidities examined included diabetes (34.5%), hyperlipidemia (44.5%),
hypertension (58.4%) and thyroid disorders (17.7%) while
rheumatoid arthritis, gout, and Parkinson’s disease were
present in less than 5% of patients (Table 1).
Case control study of incident cases of primary AC
and rotator cuff tears as controls

The final sample for analysis included 7,232 individuals with newly diagnosed primary AC and 21,727 newly
diagnosed rotator cuff tears matched to cases on age and
gender. By design, gender and age distributions were
the same with 35.8% male and a mean age of 74.8 years
(Table 2). AC and rotator cuff patients came from all
regions of the United States with a larger proportion
of AC patients having a CCI score of 2 or more (45.3%)
compared to only 41.2% of rotator cuff controls with a
CCI score of two or more. Many factors reached statistical significance in comparing the two groups, but the
actual differences in proportions between cases and controls were not clinically meaningful.
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Table.1 Patient Characteristics for all 2011 U.S. Medicare
Beneficiaries diagnosed with Adhesive Capsulitis
All Adhesive
Capsulitis
Cases
(N = 92,437)
N (%)
Male

33,012 (35.7)

Race
Asian

2,628 (2.8)

Black

6,199 (6.7)

Hispanic

1,620 (1.8)

Other

2,186 (2.4)

White

79,804 (86.3)

Dual eligible for Medicaida

10,999 (11.9)

Mean Age (Standard Deviation)

75.7 (7.0)

Age Group
66–69

24,026 (26.0)

70–75

29,143 (31.5)

76–79

14,380 (15.6)

80–85

15,628 (16.9)

86 +

9,260 (10.0)

Midwest

18,758 (20.3)

Northeast

19,310 (20.9)

South

37,440 (40.5)

West

16,334 (17.7)

Region

Charlson Comorbidity Index (CCI)
0

24,775 (26.8)

1

20,391 (22.1)

2

14,683 (15.9)

Assessment of seasonality

3

11,426 (12.4)

The proportion of new cases diagnosed by month was
plotted for AC and rotator cuff tear patients (Fig. 2).
While the highest proportion of AC cases were diagnosed
in the last 5 months of the year, particularly in November and December (9.6% and 9.8%, respectively), these
numbers did not exceed 2 standard deviations above the
mean monthly proportion of 8.3% ± 1.6%. Similarly, there
was no apparent seasonal trend for rotator cuff tears as
all months were within the monthly mean of 8.3% ± 1.3%.

4+

21,162 (22.9)

0

34,721 (37.6)

1

30,776 (33.3)

Frailty Risk Index (FRI)

2

13,593 (14.7)

3+

13,347 (14.4)

Mean Previous Year Medicare Spending (SD)b

$14,176 (23,287)

Comorbidities
Diabetes, Type 1

3,220 (3.5)

Diabetes, Type 2

28,611 (31.0)

Prevalence of comorbid health conditions

Hyperlipidemia

41,106 (44.5)

The prevalence of known co-morbid conditions and risk
factors for AC were compared for primary AC cases
and rotator cuff tear controls (Table 3). The odds of having AC was significantly higher for those beneficiaries
with Type 1 diabetes compared to those without diabetes (odds ratios of 1.37 (95% CI 1.17–1.61) and for Type
2 diabetes (OR = 1.22 (95% CI 1.14–1.29). Parkinson’s
disease, although uncommon, also showed a positive
association with AC with an odds ratio of 1.58 (95% CI
1.23–2.04). Hypertension, hyperlipidemia, and thyroid

Hypertension

53,979 (58.4)

Thyroid Disorder

16,364 (17.7)

Rheumatoid arthritis

3,883 (4.2)

Gout

2,744 (3.0)

Parkinson’s Disease

1,299 (1.4)

a

Beneficiary was fully dual-eligible for Medicare and Medicaid during the
month the index shoulder visit occurred

b

Total Part A and B payments made by Medicare for the beneficiary over the
period of 365-days prior to their index shoulder date
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Table.2 Comparison of Patient Characteristics for Incident Adhesive Capsulitis Cases and Matched Rotator Cuff Tear Controls
Adhesive Capsulitis Cases
(N = 7,232)

Rotator Cuff Tear Controls
(N = 21,694)

2,592 (35.8)

7,776 (35.8)

N (%)

Male

p

N (%)

0.99
< 0.0001

Race
Asian

133 (1.8)

175 (0.8)

Black

453 (6.3)

1,037 (4.8)

Hispanic

73 (1.0)

251 (1.2)

Other

183 (2.5)

311 (1.4)

White

6,390 (88.4)

19,920 (91.8)

Dual eligible for Medicaida

513 (7.1)

1,111 (5.1)

< 0.0001

Mean Age (Standard Deviation)

74.8 (6.8)

74.9 (6.7)

0.11

66–69

2,278 (31.5)

6,449 (29.7)

70–75

2,303 (31.8)

7,218 (33.3)

76–79

1,011 (14.0)

3,073 (14.2)

80–85

1,063 (14.7)

3,266 (15.1)

86 +

577 (8.0)

1,688 (7.8)

Midwest

1,641 (22.7)

4,909 (22.6)

Northeast

1,449 (20.0)

4,019 (18.5)

South

2,955 (40.9)

8,824 (40.7)

West

1,136 (15.7)

3,849 (17.7)

0

2,369 (32.8)

7,754 (35.7)

1

1,582 (21.9)

5,005 (23.1)

2

1,045 (14.4)

3,444 (15.9)

3

881 (12.2)

2,350 (10.8)

4+

1,355 (18.7)

3,141 (14.5)

0

4,161 (57.5)

12,487 (57.6)

1

1,822 (25.2)

5,699 (26.3)

2

675 (9.3)

2,106 (9.7)

3+

574 (7.9)

1,402 (6.5)

$10,174 (20,995)

$8,130 (14,971)

0.04

Age Group, years

< 0.0001

Region

< 0.0001

Charlson Comorbidity Index (CCI)

< 0.0001

Frailty Risk Index (FRI)

Mean Previous Year Medicare Spending (SD)b
a

Beneficiary was fully dual-eligible for Medicare and Medicaid during the month the index shoulder visit occurred

b

Total Part A and B payments made by Medicare for the beneficiary over the period of 365-days prior to their index shoulder date

disorders were prevalent for both cases and controls but
no significant association was made with AC.
Association with medications taken prior to diagnosis

The association with medications of a priori interest was
investigated. After adjusting for age, gender, and the two
significant comorbid conditions, diabetes and Parkinson’s
disease, we found that odds of having AC was lower for
individuals taking a quinolone antibiotic (OR = 0.88, 95%
CI 0.79–0.97) in the 180-days prior to the index shoulder
diagnosis (Table 4). No association was found for receiving an influenza or pneumococcal vaccination or taking

a barbiturate or antiviral class of medication and having a diagnosis of AC. Recorded usage of barbiturates in
the sample was low (0.3%). Too few individuals (< 10 per
group) were identified who took retinoids, anti-mycobacterials, protease inhibitors, or metalloproteinase inhibitors to allow robust analysis in this investigation.
Association with infection or trauma prior to diagnosis

Five infectious disease classes occurred in at least 3%
of the population in the 180 days prior to diagnosis and
were examined as potential precipitating factors for
AC (Table 5). Upper respiratory tract infections were
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Fig. 2 Monthly seasonal distribution of diagnoses for adhesive capsulitis and rotator cuff tears, adults ages 65 and older, 2011 U.S. Medicare Data.
Error bars show 1 SD of 0.8% for AC and 0.6% for RCT. The average line shows the expectation of 8.3% of diagnoses to occur each month if there is
no monthly variation

Table.3 Univariate and unconditional logistic regression
analyses of the associations between medical comorbidities and
diagnosis of adhesive capsulitis
Cases
Medical Comorbidities N (%)

Controls

Adjusted Odds
Ratioa

N (%)

OR

95% CI
(0.95, 1.10)

Thyroid disorder

1,181 (16.3) 3,446 (15.9)

1.02

Diabetes, Type 1

243 (3.4)

1.37 (1.17, 1.61)

Diabetes, Type 2

2,149 (29.7) 5,480 (25.3)

1.22 (1.14, 1.29)

Hyperlipidemia

3,242 (44.8) 9,543 (44.0)

1.03

(0.97, 1.08)

Hypertension

3,886 (53.7) 11,661 (53.8) 0.98

(0.93, 1.04)

476 (2.2)

Rheumatoid Arthritis

131 (1.8)

452 (2.1)

0.85

(0.70, 1.04)

Gout

181 (2.5)

471 (2.2)

1.13

(0.95, 1.34)

Parkinson’s Disease

92 (1.3)

175 (0.8)

1.58 (1.23, 2.04)

a

Model was adjusted for age and gender

common, occurring in 10.3% of people with AC and
12% in people with rotator cuff tears. People with AC
were less likely to have had an upper respiratory infection prior to diagnosis than people with rotator cuff tears
(OR = 0.84, 95% CI 0.77–0.92). Lower respiratory infections were less common at 3.5% of cases and controls. No
association was observed for mycoses or infections of the
lower respiratory tract, kidney or urinary tract, or skin
prior to diagnosis. No significant difference was observed
for having a non-shoulder related fracture or sprain or

Table.4 Univariate and unconditional logistic regression
analyses of the associations between medication utilization and
diagnosis of adhesive capsulitis
Cases

Controls

Adjusted Odds
Ratio (OR)a

Medical Utilization

N (%)

N (%)

OR

95% CI

Influenza or pneumococcal vaccine

2,301 (31.8)

6,788 (31.3)

1.02

(0.96, 1.08)

Quinolones

545 (7.5)

1,815 (8.4)

0.88

(0.79, 0.97)

Barbiturates

19 (0.3)

46 (0.2)

1.22

(0.71, 2.09)

Antivirals

106 (1.5)

382 (1.8)

0.85

(0.68, 1.06)

a

Model was adjusted for age, gender, diabetes type 1, diabetes type 2 and
Parkinson’s disease

other trauma prior to diagnosis in the AC group compared to rotator cuff tear group. Approximately 6–7%
of cases and controls experienced these types of trauma
prior to diagnosis.

Discussion
Background and rationale

While AC has been studied in middle-aged adults, less is
known about its epidemiology in the elderly population.
In addition, little is known about the inciting trigger that
leads to the development of primary AC. Therefore, this
case control study was undertaken to describe AC among
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Table.5 Univariate and unconditional logistic regression
analyses of the associations between infectious disease triggers,
trauma and diagnosis of adhesive capsulitis
Cases

Controls

Adjusted Odds
Ratio (OR)a

N (%)

N (%)

OR

95% CI

Mycoses

703 (9.7)

1,895 (8.7)

1.09

(0.99, 1.20)

Upper respiratory

745 (10.3) 2,605 (12.0) 0.84 (0.77, 0.92)

Infectious Triggers

Lower respiratory

256 (3.5)

761 (3.5)

1.05

(0.91, 1.22)

Kidney or urinary

640 (8.8)

1,782 (8.2)

1.09

(0.99, 1.20)

Skin infection

333 (4.6)

934 (4.3)

1.06

(0.93, 1.21)

Traumab
442 (6.1)

1,451 (6.7)

0.91

(0.82, 1.02)

Other traumatic injuries 471 (6.5)

Fracture or sprain

1,526 (7.0)

0.92

(0.83, 1.03)

a

Model was adjusted for age, gender, diabetes type 1, diabetes type 2,
Parkinson’s disease and quinolones

b

Excludes shoulder-related traumas

the elderly and explore the hypotheses that exposure to
selected medications, distal traumas, or seasonal factors,
may increase the risk for AC.
Limitations

There were some limitations to this analysis. While three
years of complete data were available, we were not able to
assess trends beyond the one-year window into the year
2011. The use of claims data reflects dates of care rather
than medical history. Date of claims diagnosis was used
to identify date of onset, yet there may have been delay
between symptom onset and seeking care. Information
such as body mass index or obesity, detailed information
on medication prescriptions, occurrence of infections not
attended to by medical professionals, and confirmation of
diagnosis of cases or controls may be less accurate using
claims data than using medical records. The 7,232 new
cases that were examined in detail may be an underestimate of the true number of new cases per year of primary
AC, as our selection criteria required diagnostic imaging whereas not all healthcare providers order imaging
to make the diagnosis. Further, patients were removed if
they had any other shoulder diagnosis in the prior year
which may have eliminated cases that had unrelated conditions and some cases may have been misdiagnosed
with another disorder. However, the selection criteria
were used in order to assess potential triggers for new
cases which required a stringent selection criteria. One
challenge in this analysis was selecting the most appropriate window to identify potential triggers. We selected
a 6-month window prior to AC diagnosis because studies of selected medication-associated AC indicated most
[25–27, 30], but not all [29], exposures occurred within

six months of diagnosis. However, associations with
long term or chronic use of medications may have been
missed. Further, the window may have been too wide for
association with infectious triggers given that reactive
arthritis typically occurs within six weeks of infection
[49]. Finally, we used patients with rotator cuff tears as a
comparison group due to the similarities in presentation
yet distinct etiology. Other investigations of AC have also
used rotator cuff tears as comparators [37, 38]. However,
the two disorders may share some underlying risk factors.
In particular, fluoroquinolone [50, 51] and influenza vaccinations [52, 53] have been found to be associated with
tendinopathy and rotator cuff tears. Future investigations
may consider the use of additional comparison groups to
investigate triggers for AC.
A strength of the study was that the prevalence of AC
in the elderly population has not been well-studied to
date. We included a large sample size representing all
cases for an entire year across the United States among
Medicare beneficiaries. The nearly universal use of Medicare among the elderly makes the findings representative
of older American adults. The large sample size allowed
the assessment of many potential risk factors, and the
claims data included information on medications, concomitant diagnoses, and procedures.
Prevalence of AC in adults over 65 years of age

The first objective was to describe the epidemiology of
AC in older adults, an age-group infrequently studied.
Although AC is not typically thought to be a condition
common among elderly adults, we estimate more than
140,000 Medicare beneficiaries were diagnosed with
primary or secondary AC in 2011, accounting for 4% of
shoulder diagnoses in this age group. We found women
were more likely to have AC than men by a ratio of 1.8 to
1. Older age did not attenuate the risk for AC in women.
Most people with AC in the study were white (86.3%),
reflecting the demographics of the U.S. Medicare population. The patients with AC commonly had other comorbid conditions including diabetes, hyperlipidemia,
hypertension, and thyroid disorders. Rheumatoid arthritis, gout, and Parkinson’s disease were present in less
than 5% of patients. These findings agree with findings
from studies of younger populations [5, 15, 16], suggesting that the effects of age do not diminish the increased
risk for women or those with chronic disease.
We also found that on average, Medicare annual spending for patients with AC was significantly higher than the
average annual beneficiary Medicare spending in 2011
[48]. The growing elderly population and prevalence of
AC in this age group suggests that AC can be a significant cause of disability for this population. Furthermore,
the higher spending for beneficiaries diagnosed with
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AC might indicate that those beneficiaries are in worse
health and require more healthcare utilization in addition to costly AC treatment.
Risk Factors for AC in adults over 65 years of age

The second objective was to investigate risk factors and
potential triggers for AC. We examined newly diagnosed
cases of AC and compared them to people with newly
diagnosed rotator cuff tears. Age and gender were similar
by study design. Elderly beneficiaries in the U.S. Medicare
population are overwhelmingly white. However, a larger
proportion of AC patients were non-white (11.6%) compared to those with rotator cuff tears (8.2%). This contrasts with earlier investigations which suggested a higher
risk of AC for white patients [54] but is supported by
more recent and larger studies which also found higher
rates in non-white patients [55]. Others have observed
higher rates for Asian ancestry individuals in particular
[13, 56].
We found that both type 1 and type 2 diabetes as well
as Parkinson’s disease were more likely in older patients
with AC. Our findings corroborate that diabetes, a wellknown risk factor for AC in the middle age population
[13, 15–17, 55], is also associated with AC in the elderly
population. The reason diabetes increases risk for AC is
unclear, although possible biological mechanisms have
been proposed. Hwang et al. identified increases in
advanced glycation end products along with increased
collagen density and fibroblast proliferation in capsular
tissue of patients with AC and diabetes [38]. Their findings support the hypothesis that increased blood glucose
levels increase the glycation of collagen proteins which
then increases cross-linking of these fibers and stiffening
of the joint. The association with Parkinson’s disease is
less well established but confirms prior reports [22]. Contrary to initial expectations for increased risk, no association was observed for thyroid disorders.
Medication Utilization, infection and trauma as potential
triggers

In addition to examining AC in the under-studied elderly
population, the novel contribution of our work was to
explore the association between plausible triggers (systemic medications, infections, seasonality, and inciting
traumatic injury) and AC. One potentially treatmentrelated risk factor (use of quinolone antimicrobial treatment) was found to be significantly less common in
patients with AC than rotator cuff tear controls. It is
possible that fluoroquinolone exposure is associated
with tendinopathy and possibly could contribute to rotator cuff tears [50]. The stronger association with rotator cuff tears prevents a true assessment of the risk of
these factors on AC. A review of Medicare prescription
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drug usage shows approximately 20% of beneficiaries had a fluoroquinolone Part D claim in 2018 making
it a potentially common risk factor. Receipt of an influenza or pneumococcal vaccination was not found to be
an increased risk, contrary to prior suggestions [57, 58].
Arias et al. suggested that antigens injected into or near
the synovial joint may lead to a localized inflammatory
response in rare cases [58]. Other studies have reported
that maladministered influenza vaccine is a risk factor
for rotator cuff tears [52, 53]. Hessee et al. recommend
training in proper vaccination administration techniques to ensure the injection enters the deltoid muscle
and avoids the bursa, tendons, ligaments, and bones of
the upper shoulder. As this association was observed for
rotator cuff tears, future investigations should include a
non-shoulder joint disorder as a comparison group. The
general anti-viral class of medications and barbiturate
medications were not found associated with AC in this
analysis. Barbiturate medications were generally not covered by Medicare in 2011 [59], which may explain the
small numbers of cases in the data. The other classes of
investigated medications (retinoids, protease inhibitors,
metalloproteinases, isoniazid) were prescribed to 0.5% or
fewer of Medicare recipients at large [60] and were too
infrequent in this dataset to assess as risk factors.
No positive association was found between AC diagnosis and five classes of infections in the six months prior
to diagnosis. Those with an upper respiratory tract infection were less likely to be diagnosed with AC. Similarly,
sustaining a non-shoulder related fracture or sprain or
another injury was not associated with AC. The claims
data do not allow in depth analysis, but it is possible rotator cuff tears could be due to trauma rather than these
factors being protective against AC.
AC was more commonly diagnosed August through
December. However, no significant seasonal trend was
observed for AC, contrary to earlier suggestions [33, 61].
No medical records were available to determine whether
the Medicare claim date for first AC visit reflects the date
the condition began or the date when care was sought.

Conclusions
While this investigation did not identify specific triggers
for AC, it did corroborate the long-known associations
with diabetes and Parkinson’s disease in the Medicare
population. Future investigations should investigate initiating triggers for the development of this common and
disabling condition.
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